Determination of HCV genotypes and viral loads in chronic hepatic Sudanese infected patients

Mohammed E. H. Ournasseir1*, Alfadel Al Obaid Omer 2, Haitham E Elawad1, Najem Aldin M. Osman1, Khalid Mohammed Khalid Al Hussain1, Abdulazeem abdulsalam I Alkhidir1.

1Department of Microbiology, Medical Laboratories Sciences, Omdurman Islamic University, Omdurman, Sudan
2Department of Microbiology, faculty of medical laboratory sciences, University of Science and technology.

Abstract

Background. Knowledge of Hepatitis C virus (HCV) genotypes is significant for arranging treatment regimes. Quantitative HCV RNA testing provides prognostic data useful in monitoring the efficacy of antiviral therapy.

Methods. A total of 1203 serum samples were collected from individuals attending out-patients units at Khartoum State and Gezera State. The study population comprises two groups. Blood donors study groups (n= 600) and chronic hepatic patients during the course of HCV infection (n= 603). Serum samples were screened using enzyme linked immune-sorbent assay (ELISA) (Biokit, A.S. Spain®). HCV positive samples (n=100) were quantified by HCV Real-TM Quant SC (Sacace Biotechnologies Italy®).

Results: Hundred HCV seropositive samples were subjected to genotyping and quantitative analysis of these samples using RT- PCR, HCV genotype 4 was the predominant genotype (92%) followed by genotype 2 (4%), Genotype 1 (2%) and 3 (2%) in different groups. The average viral load of the patients infected with genotype 4 was higher than an average viral load of the patients infected with genotypes 1,2 and 3.

Conclusions: The present study highlighted that genotype 4 is the predominant genotype in Sudanese hepatic patients followed by genotype 2. The severity of liver disease was more among genotype 4 patients as assessed by a higher viral load.

Key words: Hepatitis C virus, genotypes, viral loads, chronic hepatic

Correspond to: Mohammed E. H. Ournasseir, Department of Microbiology, Medical Laboratories Sciences, Omdurman Islamic University Email: ornaser@hotmail.com/
Introduction

Hepatitis C infection (HCV) was recognized in 1989 and was observed to be in charge of 70-90% of post-transfusion hepatitis in all countries wherever blood was tested for Hepatitis B infection (HBV) [1]. At least six major HCV genotypes involving various, more closely related subtypes have been identified [2]. HCV genotypes show significant variations in their worldwide distribution and predominance, making genotyping a helpful technique for determining the source of HCV transmission in an infected localized population [3]. Infection by HCV is the main cause of chronic liver disease worldwide [4], the patients uninformed of their disease and at risk for developing cirrhosis and hepatocellular carcinoma[5]. HCV is an enveloped virus that has a place with the family Flaviviridae. Its linear positive-stranded RNA genome of approximately 9.6 kb in length encodes both structural (E1, E2 and core) and nonstructural (N2, NS3, NS4a/b, p7 and NS5a/b) proteins in a single open reading frame, flanked by short conserved untranslated regions (UTRs) located at the 5\’ and 3\’ ends of the genome that are required for viral replication and protein translation [6,7]. Humans appear to be the only source of infection and inoculation with blood and blood products are the most recognized mode of transmission [8]. The majority of the acute infections are symptomless with around 10% of patients having a mild flu-like illness with jaundice and an increase in blood serum aminotransferase. Hepatitis C virus (HCV) is the dominant part of parenteral and sporadic non-A- non-B hepatitis cases. At least 70% of infected patients develop chronic infection and approximately 20% progress to cirrhosis of the liver [9,11]. In spite of the fact that hepatitis C virus (HCV) infection is a major cause of chronic liver disease around the world, the virus has not yet been cultured in vitro and little is understood regarding its biological and physicochemical properties. Till sensitive and accurate test become available, diagnosing of HCV is usually done by exclusion of a high-risk individual with negative markers for HAV and HBV and also on clinical and epidemiologic features of the individual patients [12, 13].

HCV RNA can be detected fourteen days after disease and anti-HCV antibodies are typically positive six weeks from infection [14]. Sensitive methods or tests also are currently available for the detection of viral nucleic acid. Antigens from nucleocapsid regions have been used to develop ELISA, the present assay ELISA-3 (3rd generation ELISA) incorporate nonstructural recombinant antigens three, four and five (NS3, NS4, and NS5) regions. The patient infected with HCV develops antibodies to numerous structural and nonstructural viral proteins. Sensitive methods or tests also are currently obtainable for the detection of viral nucleic acid. For example RT-PCR can detect HCV-RNA in the blood however it is possibly used when serological tests gave obscure results as were as and in selecting for, and estimating response to therapy [15,16]. The absence of convenient culture system for HCV implies the utilization of molecular biology to evaluate viremia. Direct hybridization of serum samples is possible however is hampered by the
low virus concentration in many patients. Amplification of viral nucleic acid by the polymerase chain reaction (PCR) gives an exceedingly sensitive and antigen-antibody-independent technique to identify continuous viral infection. Although a positive PCR assay is not absolute verification of HCV viremia, it strongly suggests active virus production inside the body [17]. The treatment plan (a combination of compounds, dosages, and duration) and therefore the virological follow-up for management of antiviral treatment in chronic HCV hepatic patients is very important, but to guarantee good monitoring of the treated patients, doctors require fast, reproducible, and sensitive molecular tools with a large scope of detection and quantification of HCV RNA in blood tests.

Objectives
In the current study, we aimed to quantify and genotype HCV in patients suffering from chronic hepatitis during the course of infection.

Materials and Methods
Enrollment of patients
Serum samples were obtained from subjects attending out-patients units in Khartoum State and Gezira State medical centers.

Sample Collection:
Blood samples were taken from 1203 individuals, including chronic hepatic patients and normal healthy blood donors upon their consent. All serum was separated from whole blood within 6 h of collection, and stored at −20°C until testing.

Extraction of HCV RNA:
Viral RNA was extracted from serum samples with QIAamp viral RNA mini kit (Qiagen, Hilden, Germany®) following the manufacturer's directions; wherever the input volume of blood serum was 170 µL and therefore the output was 60 µL.

Reverse Transcription of HCV RNA
Reverse transcription was carried out using RT-G-mix-1 and RT-mix., were thawed, vortex and centrifuged briefly. Reaction Mix were prepared: by added 5.0µl RT-G-mix-1 into the tube containing RT-mix and vortex for at least 5-10 seconds, centrifuged briefly. 6 µl M-MLV were added into the tube with Reagent. Then it were mixed by pipetting, vortexes for 3 sec, centrifuged for 5-7 sec (must be used immediately after the preparation).10 µ of Reaction Mix were added into each sample tube.10µl RNA samples were pipetted to the appropriate tube. A, re-centrifuge all the tubes with extracted RNA for 2 minutes were done at maximum speed (12000-16000 g) and carefully supernatant were taken. Tubes were placed into thermal cycler and incubated at 37°C for 30 minutes. Each obtained cDNA sample was diluted 1:2 with TE-buffer and centrifuged briefly the tubes. cDNA specimens could be stored at -20°C for a week or at -70°C up to one year.

Result
Analytical specificity and Linearity: The standard calibration curve was generated, using the Smart Cycler II software and serial dilution. The analytical specificity of the primers and the probes was validated with 80 negative samples. They did not generate any signal with the specific
HCV primers and probes. The specificity of the kit HCV Real-TM Quant was 100%. The linearity of the HCV Real-TM Quant assay was tested with the HCV RNA Standard and its dilution using HCV-negative human plasma. Each dilution was analyzed three times and the mean HCV RNA titer of each sample was determined.

Figure 1. The R-PCR amplification plot of standard control of HCV, the point that the fluorescence signal increased above baseline is the threshold cycle (CT). Each plot corresponds to a particular input target quantity marked by a corresponding symbol. The X axis denotes the cycle number of a quantitative PCR reaction. The Y axis denotes the fluorescence intensity.

Figure 2. Plot of the threshold cycle (CT) against the input target quantity (common log scale). The input target quantity was expressed as copies of HCV cDNA. The correlation coefficient is 0.994.
A total of 1203 samples were obtained from chronic hepatic patients during the course of infection as study groups (n= 600) and normal healthy blood donors represent a control (n= 603). The collected samples were screened for the HCV and HBV antibodies using ELISA. Of the 600 normal healthy blood donors which were screened for the presence of anti HCV/HBV antibodies, 8 out 600 (1.3%) showed HCV positive while 17 out of 600 (2.8%) were HBV positive. Serological screening was carried out for chronic hepatic patients during the course of infection, we found that 92 out 603 (15.2%) were positive for HCV antibodies, while 107 out 603 of (17.7%) showed positive HBV antibodies. (Table I).

Table (1): Seroprevalence of HCV and HBV infection in all groups

<table>
<thead>
<tr>
<th>Types of hepatitis</th>
<th>Blood donors</th>
<th>Chronic hepatic patients</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>positive</td>
<td>positive</td>
<td></td>
</tr>
<tr>
<td>HCV</td>
<td>8/600 (1.3%)</td>
<td>92/603 (15.2%)</td>
<td>100 (16.6)</td>
</tr>
<tr>
<td>HBV</td>
<td>17/600 (2.8%)</td>
<td>107/603 (17.7%)</td>
<td>124 (20.6%)</td>
</tr>
<tr>
<td>Total of hepatic patients</td>
<td>25/600 (4.1%)</td>
<td>199/603 (32.9%)</td>
<td>224</td>
</tr>
</tbody>
</table>

Detection of Plasma Cell-free HCV RNA in chronic hepatic patients

The HCV antibody positive samples were tested for the presence of HCV RNA. A molecular study was conducted to investigate the prevalence of Hepatitis C virus genotypes in HCV infected population of Khartoum state. 100 HCV seropositive samples were subjected to genotyping and quantitative analysis of these samples using RT-PCR. HCV genotype 4 was the predominant genotype (92%) followed by genotype 2 (4%), Genotype 1 (2%) and 3 (2%)(Table 2).

Table 2: Distribution of HCV genotypes in all study population

<table>
<thead>
<tr>
<th>HCV Genotype</th>
<th>Blood donors</th>
<th>Chronic hepatic</th>
<th>Total samples</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotype 1</td>
<td>0.0</td>
<td>2.0</td>
<td>2 (2%)</td>
</tr>
<tr>
<td>Genotype 2</td>
<td>0.0</td>
<td>4.0</td>
<td>4 (4%)</td>
</tr>
<tr>
<td>Genotype 3</td>
<td>1.0</td>
<td>1.0</td>
<td>1 (1%)</td>
</tr>
<tr>
<td>Genotype 4</td>
<td>7.0</td>
<td>85</td>
<td>92 (92%)</td>
</tr>
<tr>
<td>Genotype 5</td>
<td>0.0</td>
<td>0.0</td>
<td>0%</td>
</tr>
<tr>
<td>Genotype 6</td>
<td>0.0</td>
<td>0.0</td>
<td>0%</td>
</tr>
<tr>
<td>Total</td>
<td>8</td>
<td>92</td>
<td>100</td>
</tr>
</tbody>
</table>
Quantitative HCVRNA –specific PCR
Viral load quantification was carried out by Taqman real time PCR system in all 100 HCV RNA positive patients and was compared between the four groups of genotypes. The average viral load of the patients infected with genotype 4 was higher than average viral load of the patients infected with genotypes 1.2 and 3 (2.76×10³ – 9.3×10⁶) copies/ml.

Discussion
In the present study the seroprevalence, genotyping and estimation of viral load (viremia) of viral hepatitis C was evaluated in sera of different groups include blood donors and hemodialysis patients, randomly selected in Khartoum area and screened by ELISA (third generation) using recombinant HCV – antigens, as well as real-time polymerase chain reaction (RT-PCR) for genotyping and quantitative viral load assay were estimated in positive individuals for HCV. In blood donors study population (8/17/600) of about (1.3/2.8 %), samples showed positive results of HCV/HBV – antibodies respectively, when tested by ELISA using recombinant HCV – antigens. A similar study was previously done in Juba town, in Southern Sudan, and 3% of the studied populations were found positive for HCV–antibodies[18]. Similarly, El-Hazmi, M (2000), also reported or highlighted the prevalence rates of HBV and HCV (1.5% and 0.4%), respectively among completely different groups. The prevalence differs from one group to another, being the most reduced among Saudi and young donors. Accordingly, extensive recruitment of Saudi and young donors should help ensure a long-term increase in the blood supply without risk. Another investigation concluded that the prevalence of HCV infection in the population recruited from different health centers in Jordan was comparatively low and estimates a prevalence of 0.42% among all age groups and 0.56% among those aged above 15 years old [19, 20]. Low values of both this study and others suggest that HCV infection is not an endemic disease in healthy blood donors. In this study HCV infection has been found high among hemedialysis patients ,(15.2%), of the whole hemodialysis samples (92/603), have been found positive to HCV–antibodies, when tested by ELISA using recombinant HCV– antigens, whereas 107 (17.7%) of HBV positive antibodies were found when tested using same technique. This is in agreement with [21]. Similarly [22,23] reported that the prevalence of HCV infection among dialysis patients was generally higher than that among healthy blood donors. Dialysis patients have an increased risk of exposure to parenterally transmit hepatitis virus. Hemodialysis machine may represent a hazard of HCV transmission of HCV antibodies positive patients. The present study is in support of the positive and have a history of presentation to a dialysis machine. Once, more results are in agreement with those obtained by [24]. However, the dialysis process itself and also the level of a hygienic standard may influence the risk level of HCV infection. Another study, in Saudi Arabia, reported that the overall of anti-HCV antibodies were detected in 7.3% (1124/15323) of the studied individuals [25].
Abdel-Aziz, F et al, 2000 reported that the high rate of anti-HCV prevalence has been assessed in Egypt of the total samples 24.3% (973/3,999). That showed the highest value, reported in a community-based study through all age groups as well as reflected, that HCV was endemic in Egypt [26]. In conclusion, the rate of risk factors that might contribute to HCV infection, we found patients, who suffered chronic disease in about 92%. This might represent the probability of hemodialysis machine in the transmission of the disease. While patients who received a blood transfusion and who suffered a history of surgery represented 24% and 6% respectively. Tattooing represented 3% and alcohol uptake individuals 0% had no role in predisposition to the disease.

References:


